Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer

Kenji Tamura, Mutsuo Furihata, Su Yong Chung, Motohide Uemura, Hiroki Yoshioka, Tatsuo Iiyama, Shingo Ashida, Yasutomo Nasu, Tomoaki Fujioka, Taro Shuin, Yusuke Nakamura, Hidewaki Nakagawa

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Prostate cancer is usually androgen-dependent and responds well to androgen ablation therapy based on castration. However, at a certain stage some prostate cancers eventually acquire a castration-resistant phenotype where they progress aggressively and show very poor response to any anticancer therapies. To characterize the molecular features of these clinical castration-resistant prostate cancers, we previously analyzed gene expression profiles by genome-wide cDNA microarrays combined with microdissection and found dozens of trans-activated genes in clinical castration-resistant prostate cancers. Among them, we report the identification of a new biomarker, stanniocalcin 2, as an overexpressed gene in castration-resistant prostate cancer cells. Real-time polymerase chain reaction and immunohistochemical analysis confirmed overexpression of stanniocalcin 2, a 302-amino-acid glycoprotein hormone, specifically in castration-resistant prostate cancer cells and aggressive castration-naïve prostate cancers with high Gleason scores (8-10). The gene was not expressed in normal prostate, nor in most indolent castration-naïve prostate cancers. Knockdown of stanniocalcin 2 expression by short interfering RNA in a prostate cancer cell line resulted in drastic attenuation of prostate cancer cell growth. Concordantly, stanniocalcin 2 overexpression in a prostate cancer cell line promoted prostate cancer cell growth, indicating its oncogenic property. These findings suggest that stanniocalcin 2 could be involved in aggressive phenotyping of prostate cancers, including castration-resistant prostate cancers, and that it should be a potential molecular target for development of new therapeutics and a diagnostic biomarker for aggressive prostate cancers.

Original languageEnglish
Pages (from-to)914-919
Number of pages6
JournalCancer Science
Volume100
Issue number5
DOIs
Publication statusPublished - 2009

Fingerprint

Castration
Prostatic Neoplasms
teleocalcin
Androgens
Biomarkers
Genes
Cell Line
Microdissection
Neoplasm Grading
Growth
Oligonucleotide Array Sequence Analysis
Transcriptome
Small Interfering RNA
Real-Time Polymerase Chain Reaction
Prostate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tamura, K., Furihata, M., Chung, S. Y., Uemura, M., Yoshioka, H., Iiyama, T., ... Nakagawa, H. (2009). Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. Cancer Science, 100(5), 914-919. https://doi.org/10.1111/j.1349-7006.2009.01117.x

Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. / Tamura, Kenji; Furihata, Mutsuo; Chung, Su Yong; Uemura, Motohide; Yoshioka, Hiroki; Iiyama, Tatsuo; Ashida, Shingo; Nasu, Yasutomo; Fujioka, Tomoaki; Shuin, Taro; Nakamura, Yusuke; Nakagawa, Hidewaki.

In: Cancer Science, Vol. 100, No. 5, 2009, p. 914-919.

Research output: Contribution to journalArticle

Tamura, K, Furihata, M, Chung, SY, Uemura, M, Yoshioka, H, Iiyama, T, Ashida, S, Nasu, Y, Fujioka, T, Shuin, T, Nakamura, Y & Nakagawa, H 2009, 'Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer', Cancer Science, vol. 100, no. 5, pp. 914-919. https://doi.org/10.1111/j.1349-7006.2009.01117.x
Tamura, Kenji ; Furihata, Mutsuo ; Chung, Su Yong ; Uemura, Motohide ; Yoshioka, Hiroki ; Iiyama, Tatsuo ; Ashida, Shingo ; Nasu, Yasutomo ; Fujioka, Tomoaki ; Shuin, Taro ; Nakamura, Yusuke ; Nakagawa, Hidewaki. / Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. In: Cancer Science. 2009 ; Vol. 100, No. 5. pp. 914-919.
@article{9a1d3a5ebe0d47ccba63d42ecd3f51d6,
title = "Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer",
abstract = "Prostate cancer is usually androgen-dependent and responds well to androgen ablation therapy based on castration. However, at a certain stage some prostate cancers eventually acquire a castration-resistant phenotype where they progress aggressively and show very poor response to any anticancer therapies. To characterize the molecular features of these clinical castration-resistant prostate cancers, we previously analyzed gene expression profiles by genome-wide cDNA microarrays combined with microdissection and found dozens of trans-activated genes in clinical castration-resistant prostate cancers. Among them, we report the identification of a new biomarker, stanniocalcin 2, as an overexpressed gene in castration-resistant prostate cancer cells. Real-time polymerase chain reaction and immunohistochemical analysis confirmed overexpression of stanniocalcin 2, a 302-amino-acid glycoprotein hormone, specifically in castration-resistant prostate cancer cells and aggressive castration-na{\"i}ve prostate cancers with high Gleason scores (8-10). The gene was not expressed in normal prostate, nor in most indolent castration-na{\"i}ve prostate cancers. Knockdown of stanniocalcin 2 expression by short interfering RNA in a prostate cancer cell line resulted in drastic attenuation of prostate cancer cell growth. Concordantly, stanniocalcin 2 overexpression in a prostate cancer cell line promoted prostate cancer cell growth, indicating its oncogenic property. These findings suggest that stanniocalcin 2 could be involved in aggressive phenotyping of prostate cancers, including castration-resistant prostate cancers, and that it should be a potential molecular target for development of new therapeutics and a diagnostic biomarker for aggressive prostate cancers.",
author = "Kenji Tamura and Mutsuo Furihata and Chung, {Su Yong} and Motohide Uemura and Hiroki Yoshioka and Tatsuo Iiyama and Shingo Ashida and Yasutomo Nasu and Tomoaki Fujioka and Taro Shuin and Yusuke Nakamura and Hidewaki Nakagawa",
year = "2009",
doi = "10.1111/j.1349-7006.2009.01117.x",
language = "English",
volume = "100",
pages = "914--919",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer

AU - Tamura, Kenji

AU - Furihata, Mutsuo

AU - Chung, Su Yong

AU - Uemura, Motohide

AU - Yoshioka, Hiroki

AU - Iiyama, Tatsuo

AU - Ashida, Shingo

AU - Nasu, Yasutomo

AU - Fujioka, Tomoaki

AU - Shuin, Taro

AU - Nakamura, Yusuke

AU - Nakagawa, Hidewaki

PY - 2009

Y1 - 2009

N2 - Prostate cancer is usually androgen-dependent and responds well to androgen ablation therapy based on castration. However, at a certain stage some prostate cancers eventually acquire a castration-resistant phenotype where they progress aggressively and show very poor response to any anticancer therapies. To characterize the molecular features of these clinical castration-resistant prostate cancers, we previously analyzed gene expression profiles by genome-wide cDNA microarrays combined with microdissection and found dozens of trans-activated genes in clinical castration-resistant prostate cancers. Among them, we report the identification of a new biomarker, stanniocalcin 2, as an overexpressed gene in castration-resistant prostate cancer cells. Real-time polymerase chain reaction and immunohistochemical analysis confirmed overexpression of stanniocalcin 2, a 302-amino-acid glycoprotein hormone, specifically in castration-resistant prostate cancer cells and aggressive castration-naïve prostate cancers with high Gleason scores (8-10). The gene was not expressed in normal prostate, nor in most indolent castration-naïve prostate cancers. Knockdown of stanniocalcin 2 expression by short interfering RNA in a prostate cancer cell line resulted in drastic attenuation of prostate cancer cell growth. Concordantly, stanniocalcin 2 overexpression in a prostate cancer cell line promoted prostate cancer cell growth, indicating its oncogenic property. These findings suggest that stanniocalcin 2 could be involved in aggressive phenotyping of prostate cancers, including castration-resistant prostate cancers, and that it should be a potential molecular target for development of new therapeutics and a diagnostic biomarker for aggressive prostate cancers.

AB - Prostate cancer is usually androgen-dependent and responds well to androgen ablation therapy based on castration. However, at a certain stage some prostate cancers eventually acquire a castration-resistant phenotype where they progress aggressively and show very poor response to any anticancer therapies. To characterize the molecular features of these clinical castration-resistant prostate cancers, we previously analyzed gene expression profiles by genome-wide cDNA microarrays combined with microdissection and found dozens of trans-activated genes in clinical castration-resistant prostate cancers. Among them, we report the identification of a new biomarker, stanniocalcin 2, as an overexpressed gene in castration-resistant prostate cancer cells. Real-time polymerase chain reaction and immunohistochemical analysis confirmed overexpression of stanniocalcin 2, a 302-amino-acid glycoprotein hormone, specifically in castration-resistant prostate cancer cells and aggressive castration-naïve prostate cancers with high Gleason scores (8-10). The gene was not expressed in normal prostate, nor in most indolent castration-naïve prostate cancers. Knockdown of stanniocalcin 2 expression by short interfering RNA in a prostate cancer cell line resulted in drastic attenuation of prostate cancer cell growth. Concordantly, stanniocalcin 2 overexpression in a prostate cancer cell line promoted prostate cancer cell growth, indicating its oncogenic property. These findings suggest that stanniocalcin 2 could be involved in aggressive phenotyping of prostate cancers, including castration-resistant prostate cancers, and that it should be a potential molecular target for development of new therapeutics and a diagnostic biomarker for aggressive prostate cancers.

UR - http://www.scopus.com/inward/record.url?scp=65349172979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349172979&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2009.01117.x

DO - 10.1111/j.1349-7006.2009.01117.x

M3 - Article

C2 - 19298603

AN - SCOPUS:65349172979

VL - 100

SP - 914

EP - 919

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 5

ER -